Swedish pharmaceutical company Orexo AB (STO:ORX) (OTCQX:ORXOY) on Thursday reported positive in-vivo proof-of-concept data for a powder-based intranasal influenza vaccine formulated with its proprietary AmorphOX drug delivery technology.

The study was conducted in collaboration with Abera Bioscience, a platform and vaccine developer.

Under a partnership established in December 2024, the partners aim to develop mucosal vaccines by combining AmorphOX with Abera's patented vaccine platform BERA.

In preclinical testing, both liquid and powder-based nasal formulations induced strong systemic (IgG) and mucosal (IgA) immune responses in serum, nasal tissue and lungs. No significant difference in immune response was observed between the two formulations.

The results support the potential of AmorphOX to deliver thermostable, cost-efficient vaccines without the need for cold chain logistics. This capability may offer advantages in pandemic preparedness by simplifying distribution and administration.